Antineoplastic

Antineoplastics
Tabine series
2-Deoxy-D-ribose [intermediate]
2-Fluoroadenosine [HOT] [intermediate]
Zomib series
(R)-BoroLeu-(+)-Pinanediol-CF3COOH [HOT] [intermediate]

 

 

 

 

 

Actinomycin D,50-76-0
Actinomycin D
Actinomycin D,50-76-0
CAS
50-76-0
Molecular Formula
C62H86N12O16
Molecular Weight
1255.4294
Systematic Name
Dactinomycin
Assay
99%
Certificate of analysis
Actinomycin D,50-76-0
View via PDF file
Actinomycin D,50-76-0
Specification
Items
Specification
Test result
Appearance
Bright-red or orange-red crystalline
powder,almost odorless;No visible evidence of contamination by foreign matter
Complies
Specific rotation
-292° to -317°
-313°
Identification
UV result conforms to the standard
The maximum absorptive wave is 241nm and 442nm.The ratio of absorbance at 241nm and 442nm is 1.3-1.5
Complies
Residual solvents
Ethanol: N.M.T:5000ppm
1750ppm
Acetone: N.M.T:5000ppm
800ppm
Ethyl acetate:N.M.T:5000ppm
1300ppm
THF: N.M.T:720ppm
200ppm
Toluene: N.M.T:890ppm
350ppm
Related substances
RRT 1.18-1.20 :N.M.T:2.0%
0.8%
RRT 1.26-1.27 : N.M.T:2.0%
0.7%
Total:N.M.T:4.0%
2.5%
Bacterial endotoxin
<100EU/MG
60EU/MG
Assay
95.0%-103.0%
98.5%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Packing
Actinomycin D,50-76-0
Packing 1
1g
Packing 2
10g
Packing 3
50g
   
   
Bulk request
sales@lanospharma.com
Related Antineoplastic Antibiotics
   
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(Actinomycin D,50-76-0).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.